T cell metabolism and immunotherapy

Iosifina (I.P.) Foskolou, PhD

CD8+ T cells are crucial players of immunity due to their paramount role in killing malignant and virally infected cells. Novel immunotherapy treatments use CD8+ T cells to eradicate cancer. In one of these treatments, the T cells are genetically modified to express artificial receptors that target specific proteins on cancer cells. This CAR-T cell therapy uses patients’ T cells to recognise and fight cancer and achieves up to 90% clinical responses against some blood cancers. However, CAR-T cells usually die early after administration, and their persistence depends on tumour type and production method. CAR-T cell therapy also shows very low efficacy against solid tumours due to low CAR-T cell infiltration within the tumour and the inhospitable tumour microenvironment. Long-lasting CAR-T cells are crucial for successful therapy and preventing disease relapse.
We investigate how to produce fitter CAR-T cells that can persist for longer and infiltrate solid tumours better. My lab aims to advance CAR-T cell therapy by focusing in two main research lines: 1) determine the effects of low oxygenation in the response of CAR-T cells within the tumours and 2) improve the production of current and new CAR-T cells by modulating their genetic background or culturing systems.

Groupleader

Iosifina (I.P.) Foskolou, PhD

Iosifina (IP) Foskolou PhD

Research lines

The Foskolou lab is establishing a research line on T cell metabolism and cancer immunotherapy. The lab aims to improve CAR (chimeric antigen receptor) T cell therapy against solid tumours by better understanding the environment CAR-T cells face both in tumours and in lymphoid organs. Our 2 main research lines are:

1) Understanding how T cells respond to low oxygenation (hypoxia)

Oxygen regulates cell metabolism, function, differentiation, and survival of immune cells. Circulating T cells encounter a wide range of oxygen levels during circulation, since most lymphoid tissues are naturally hypoxic (bone marrow 6% O2, spleens 2.9% O2, thymus 0-2% O2). T cells also face oxygen limitation in solid tumours and inflammatory tissues. Hypoxia affects T cell metabolism, function, and differentiation but the effect of hypoxia on T cell responses is rarely investigated. The Foskolou group aims to determine how low oxygenation can be used to achieve beneficial T cell responses, and to find the mechanisms underlying how severe and continuous hypoxia becomes detrimental. We have recently shown that hypoxia and hypoxia-induced metabolites can alter the T cell differentiation status and enhance anti-tumour activity in CAR-T cell therapies. Uncovering the mechanisms by which hypoxia has both beneficial and detrimental effects can help to design better CAR-T cells with higher persistence and to understand how these CAR-T cells can better handle the tumour microenvironment.

2) Finding new CAR-T cell production methods to increase therapy outcome

We recently showed that CAR-T cells that are maintained in a less differentiated phenotype (i.e., multipotent or central memory T cells) during manufacturing display better expansion, anti-tumour activity and persistence. To create multipotent and central memory CAR-T cells we either genetically modify the CAR-T cells using CRISPR/Cas 9 gene editing or we treat the CAR-T cells with specific inhibitors and metabolites. The targets we currently investigate are epigenetic (TET2, KDMs) and epitranscriptomic modifiers (METTL3, FTO, ALKBH5). Optimising the CAR-T cell culturing and manufacturing conditions has strong potential to advance CAR-T cell immunotherapy.

Key publications

Bargiela D, Cunha PP, Velica P, Krause LCM, Brice M, Barbieri L, Gojkovic M, Foskolou IP, Rundqvist H, Johnson RS. The Factor Inhibiting HIF regulates T cell differentiation and anti-tumour efficacy. Frontiers in Immunology 2024 

Foskolou IP*, Cunha PP, Sánchez-López E, Minogue EA, Nicolet BP, Guislain A, Jorgensen C, Kostidis S, Zandhuis ND, Barbieri L, Bargiela D, Nathanael D, Tyrakis PA, Palazon A, Giera M, Wolkers MC, Johnson RS*. The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function. Cell Reports 2023 

Minogue EA, Cunha PP, Wadsworth BJ, Grice GL, Sah-Teli SK, Hughes R, Bargiela D, Quaranta A, Zurita J, Antrobus R, Velica P, Barbieri L, Wheelock CE, Koivunen P, Nathan JA, Foskolou IP, Johnson RS. Glutarate regulates T cell metabolism and anti-tumour immunity. Nature Metabolism 2023 

Foskolou IP, Lukas Bunse, Jan Van den Bossche. 2-hydroxyglutarate rides the cancer-immunity cycle. Current Opinion in Biotechnology 2023

Cunha PP, Minogue E, Krause LCM, Hess RM, Bargiela D, Wadsworth BJ, Barbieri L, Brombach C, Foskolou IP, Bogeski I, Veliça P, Johnson RS. Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy. Elife 2023 

Barbieri L, Velica P, Gameiro PA, Cunha PP, Foskolou IP, Rullman E, Bargiela D, Johnson RS, Rundqvist H. Lactate exposure shapes the metabolic and transcriptomic profile of CD8+ T cells. Frontiers in Immunology 2023

Matuleviciute R, Cunha PP, Johnson RS*, Foskolou IP*. TET-driven epigenetic alterations in hypoxia and cancer. The FEBS journal 2021 

Veliça P, Cunha PP, Vojnovic N, Foskolou IP, Bargiela D, Gojkovic M, Rundqvist H, Johnson RS. Modified Hypoxia Inducible Factor expression in CD8+ T cells increases anti-tumor efficacy. Cancer Immunology Research 2021 

Foskolou IP, Barbieri L, Vernet A, Bargiela D, Cunha PP, Veliça P, Suh E, Pietsch S, Matuleviciute R, Rundqvist H, McIntyre D, Smith KGC, Johnson RS. The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T outcome. Blood Advances 2020

Foskolou IP, Jorgensen C, Leszczynska KB, Olcina MM, Tarhonskaya H, Haisma B, D’Angiolella V, Myers WK, Domene C, Flashman E, Hammond EM. Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication. Molecular Cell 2017

Funding

  • Joghem van Loghem (JvL)
  • Cancer Research Amsterdam (CCA)
  • Horizon Europe Marie Skłodowska-Curie Actions (MSCA)
  • Horizon Europe programme grant (HIT-GLIO)
Group members

Iosifina (I.P.) Foskolou, PhD

Group leader
MSCA-fellow
Iosifina (IP) Foskolou PhD

Joana (J.S.) Akoto

PhD-student
Joana (JS) Akoto

Jules (J.) Al Samara

Intern
Jules Al Samara

Yumna (Y.A.) Butt

PhD-student
Yumna (YA) Butt

Michel (M.) Driessen

Technician
Michel (M) Driessen

Bas (B.) Hulsebos

Intern
Bas Hulsebos

Nordin (N.) Zandhuis

Postdoc
Nordin (N.) Zandhuis